AbbVie Buying DJS Antibodies for $255 Million

By Colin Kellaher

AbbVie Inc. on Thursday said it agreed to buy U.K.-based biotechnology company DJS Antibodies Ltd. for $255 million in cash in a deal that bolsters its immunology pipeline.

The North Chicago, Ill., biopharmaceutical company said DJS's lead program, DJS-002, is a potential first-in-class lysophosphatidic acid receptor 1 antagonist antibody currently in preclinical studies for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases.

AbbVie said DJS's investors, which include Oxford Science Enterprises, Johnson & Johnson Innovation Ltd., LifeArc, Sedgwick Yard and Amgen Ventures, are eligible for potential additional payments based on the achievement of certain milestones related the DJS-002 program.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 20, 2022 09:31 ET (13:31 GMT)

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2024 to Aug 2024